Phase 2 N=20 UCDCC#271: Phase I/II Trial of Epacadostat, Intralesional SD101, Radiotherapy in Patients With Lymphoma
Advanced Solid Tumors · Lymphoma
Primary: Maximum Tolerated Dose (MTD) — 300 mg
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=49 Ketorolac as an Adjuvant Agent for Postoperative Pain Control Following Arthroscopic ACL Surgery
ACL Injury · Postoperative Pain
Primary: Postoperative Visual Analogue Scale Scores — 50.4; 40.0 score on a scale
N/A N=820 The Doctors for Coronavirus Prevention Project Thanksgiving / Christmas Messaging Campaign
Covid19
Primary: Facebook Movement Metric — -6.082; -5.320; -2.603; -1.823 Percent change relative to Feb 2020
Phase 3 N=3,689 VELOCITY: An Anthrax Vaccine Clinical Study
Anthrax
Primary: Geometric Mean Titer (GMT) of Toxin Neutralizing Antibody (TNA) 50% Neutralization Factor (NF50) at Day 64 — 0.765; 0.741; 0.716; 0.330 Titer (TNA NF50)
Phase 2 N=15 Plus Epicatechin Duchenne Muscular Dystrophy in Non-ambulatory Adolescents
Duchenne Muscular Dystrophy
Primary: Pharmacokinetics Outcome: Absolute Values of (+)-Epicatechin Serum Concentration, Pre-dose (Trough) and 2 Hours Post-dose (Peak) — 15.1; 33.9; 20.6; 481.2 nM — p=0.0482
N/A N=47 Navigation of the Pelvic Floor in Bladder Exstrophy Using Pre-operative MRI
Bladder Exstrophy
Primary: Success or Failure of Exstrophy Closure — 44; 0 exstrophy closures
N/A N=230 Dario™ Blood Glucose Monitoring System - User Performance Evaluation
Diabetes
Primary: BGMS Accuracy Assessment When Used by Layperson — 2; 4; 6; 44 percentage of participants
Phase 2 N=252 Brodalumab (AMG 827) in Rheumatoid Arthritis (RA) Participants With Inadequate Response to Methotrexate
Rheumatoid Arthritis
Primary: Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 12 — 12.7; 15.9; 15.9; 9.5 percentage of participants — p=0.598
Phase 3 N=346 Calcineurin Inhibitor-Free Interventions BMT CTN 1301 for Prevention of Graft-versus-Host Disease (BMT CTN 1301)
Acute Leukemia · Myelodysplasia
Primary: Chronic GVHD-free, Relapse-free Survival (CRFS) Probability — 60.2; 60.3; 52.6; 50.6 percentage of participants — p=0.2368
Phase 1 N=7 Radiolabeled Monoclonal Antibody in Treating Patients With Advanced Ovarian Epithelial Cancer
Ovarian Cancer
Primary: Number of Patients With Dose-limiting Toxicities (DLTs) — 0; 0 Participants
Phase 3 N=180 TMC125-TiDP35-C239 - Continued Access to Etravirine (ETR) in Treatment Experienced HIV-1 Infected Participants
HIV Infections · HIV-1
Primary: Number of Participants With At-least One Adverse Event as a Measure of Safety Until Etravirine (ETR)-Based Treatment Regimen is Commercially Available — 42 Participants
Phase 3 N=57 A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With Inhibitors
Hemophilia A · Hemophilia B
Primary: Estimated Annualized Bleeding Rate (ABR) for Treated Bleeds During the Efficacy Period — 18.071; 1.666 episodes per participant per year — p=<0.0001
Phase 2 N=84 Study of BTK Inhibitor, Ibrutinib in Combination With Carfilzomib in Subjects With Relapsed and Refractory Multiple Myeloma
Multiple Myeloma
Primary: Overall Response Rate (ORR) — 2; 2; 12; 42 Participants
N/A N=160 Infra Red Vein Visualization: Efficacy vs. Standard Technique
Difficult Intravenous Access
Primary: Success Rate — 84.81; 90 percentage of participants — p=0.34
Phase 3 N=558 Safety and Efficacy of ADS-5102 in Multiple Sclerosis Patients With Walking Impairment
Walking Impairment · Multiple Sclerosis
Primary: Timed 25 Foot Walk (T25FW, Feet/Second): the Proportion of Subjects With a ≥ 20% Increase in Walking Speed (Measured by T25FW) From Baseline at Week 16 (Responder…